Here is something researchers did not think was possible until recently: repairing damaged nerve cells in the adult retina. A new study suggests a single treatment may be able to do exactly that, and even reverse vision loss.
The key is a gene called CaBP4. When that gene is not working properly, two important structures inside the eye fail to develop as they should. The outer plexiform layer, which holds crucial connectors for vision, stays stunted. So do the synaptic ribbons inside the eye’s light-sensing cells.
The study comes from Michigan State University and was published in the journal Molecular Therapy Advances. The team treated whippet dogs born with a faulty copy of that gene. People can inherit the same rare flaw, and in both species it causes poor vision from childhood, especially in dim light.
Lead researcher Billie Beckwith-Cohen compares the faulty gene to a typo in a blueprint. The instructions become unreadable, so the eye gets built wrong. The fix was a single injection. A harmless virus carried a working copy of the gene into the retina, like handing the builders a corrected page.
The treatment targeted that gene problem. And the results went beyond what researchers expected. Not only did the outer plexiform layer and synaptic ribbons expand, but damaged areas of the retina also degraded less than they would have otherwise.
The dogs’ vision improved substantially, most of all in low light. The benefits lasted, too, with some animals followed for up to three years.
What makes this especially notable is where the treatment was tested. Human nerve cells (including the ones in your eyes) have long been considered beyond repair once damaged. Adult retinas, researchers believed, simply could not regenerate. This study challenges that assumption directly.
The CaBP4 condition is rare. The bigger lesson is that adult eye tissue can still rebuild its wiring. And a related idea is already being tested in people.
Harvard geneticist David Sinclair has spent two decades studying why cells age. His view: our cells keep their DNA over the years but gradually lose track of which genes to use. Picture a library where every book is still on the shelf, but the catalog has been scrambled.
A company Sinclair co-founded, Life Biosciences, developed a one-time eye injection called ER-100, designed to restore that order. It targets the cells that carry signals from the eye to the brain, which do not grow back on their own. After encouraging results in mice and monkeys, the FDA cleared a first human trial in January 2026. The first patient was treated in June.
Volunteers between 40 and 85 are enrolled. Some have glaucoma, one of the most common causes of blindness as people age. Others have NAION, a sudden loss of blood flow to the optic nerve that currently has no approved treatment.
The first results came out on October 8. The company reported that three glaucoma patients handled the treatment well over eight weeks, with no serious side effects. In two of them, more than a quarter of the spots checked on a standard peripheral vision test showed better light detection. A safety board approved moving to a higher dose.
Three patients is a very small number, and there was no comparison group, so this is far from proof. It is, however, the first time a therapy of this kind has been tested in human eyes.
For those of us who worry about our eyesight as we get older, research like this is worth paying attention to. Vision loss is one of the things people in our generation fear most about aging. The idea that a one-time treatment could one day address the damage, not just slow it down, is a real shift in thinking.
This is still early-stage research, and the study authors note that more work lies ahead. But the direction is encouraging. Science that once said certain damage was permanent is now asking a different question: what if it does not have to be?
